Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
From the latest AZ Results........
They're doing a lot of work and research into breast cancer.....AGL's domain.
'US approvals for Tagrisso with the addition of chemotherapy for EGFRm NSCLC (FLAURA2), Enhertu in HER2-positive solid tumours (DESTINY-PanTumor02, DESTINY-Lung01, DESTINY-CRC02) and Ultomiris for NMOSD. US and EU approval for Voydeya as an add-on therapy to Ultomiris or Soliris for PNH with EVH (ALPHA). Japan approval for Truqap plus Faslodex in unresectable or recurrent PIK3CA-, AKT1-, or PTEN-altered HR-positive, HER2-negative breast cancer (CAPItello-291).
‒ Datopotamab deruxtecan BLAs accepted in the US for non-squamous NSCLC (TROPION-Lung01) and HR-positive, HER2-negative breast cancer (TROPION-Breast01)
ANGLE is also working to expand its DDR work with other large pharma customers and continues to generate significant new customer interest through its business development activity."
A placing with more hype........is doomed to fail.
Look on the bright side....if they were going to raise money, they would have done it, at the higher price, before now.
'Anyone with a short position is going to get slaughtered IMHO. '
Let the market do its work.....MM's are very clever people.....they too have got to make money.
The shorters are 'Bustin a gut over this one;....but try not to lose the plot...It's no where near as bad as has been portrayed.
https://finance.yahoo.com/news/angle-receives-fda-clearance-parsortix-120000516.html?fr=sycsrp_catchall
1.5p spread....that's the way you control shorters
'Watch for the rise into the close as all the late passengers board the AGL bus.....'
A penny on the way down, a penny the way up....The MM's love this one. (Personaly I'm disappointed with the re-rampers....I was looking forward to 15/16p....you've let me down.
'This finding is particularly significant as it includes mutations that are targeted by FDA-approved cancer drugs, yet were missed by traditional ctDNA analysis.'
Of course the FDA are going to approve clearance for further research ....because it looks as if the FDA themselves have missed something by already allowing approval to cancer drugs that are not 100% effective..
Rise Monday?....Check the 1D Intraday chart...
https://www.londonstockexchange.com/stock/AGL/angle-plc/company-page
i believe he's still here.
https://*********************/newsfeed/article/pantheon-resources-replacement-tr-1-notification-of-major-holdings-2060926
I imagine the same will happen here...when Mangrove covers their short.
'Petrofac up 50% as shorters cash out after big new order'
Published: 08:37 20 Dec 2023 GMT
'OMG there are to many big numbers in this RNS its blowing my mind. '
Yep...2025 and 2028....too big for me., sounds like 'stick-em in the bottom draw numbers'
Are Mangrove on the move?
https://www.lse.co.uk/ShareShortPositions.html?shareprice=PANR&share=Pantheon-Res
Https://www.valuewalk.com/bofa-analysts-oil-could-go-to-250/
' 3 or 4 suitors whom are or have thrown their hats in the ring and now jay and the team have the luxury of picking one ..'
Prudence demands that the current 'state of play' would be to keep a low profile on the events surrounding PANR so as to attract the best suitors.Jacking the valuation up prior to negotiating a suitor could make the task more difficult ending up shooting themselves in the foot.
Prudence
'They are not targeting the maximum flow rate. It's more about gathering data they say.'
still...it would nice to have the quantities confirmed.. This would give them a valuable negotiable asset.